p53 in senescence – it's a marathon, not a sprint

The tumour suppressor p53, a stress‐responsive transcription factor, plays a central role in cellular senescence. The role of p53 in senescence‐associated stable proliferative arrest has been extensively studied. However, increasing evidence indicates that p53 also modulates the ability of senescent cells to produce and secrete diverse bioactive factors (collectively called the senescence‐associated secretory phenotype, SASP). Senescence has been linked with both physiological and pathological conditions, the latter including ageing, cancer and other age‐related disorders, in part through the SASP. Cellular functions are generally dictated by the expression profile of lineage‐specific genes. Indeed, expression of SASP factors and their regulators are often biased by cell type. In addition, emerging evidence suggests that p53 contributes to deregulation of more stringent lineage‐specific genes during senescence. P53 itself is also tightly regulated at the protein level. In contrast to the rapid and transient activity of p53 upon stress (‘acute‐p53’), during senescence and other prolonged pathological conditions, p53 activities are sustained and fine‐tuned through a combination of different inputs and outputs (‘chronic‐p53’).

[1]  Hu Li,et al.  p21 produces a bioactive secretome that places stressed cells under immunosurveillance , 2021, Science.

[2]  Dong Eun Kim,et al.  Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis. , 2021, Cell metabolism.

[3]  T. Hughes,et al.  The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. , 2021, Immunity.

[4]  Yoko Ito,et al.  COX2 regulates senescence secretome composition and senescence surveillance through PGE2 , 2021, Cell reports.

[5]  Yoko Ito,et al.  Locus-specific induction of gene expression from heterochromatin loci during cellular senescence , 2020, Nature Aging.

[6]  T. Stiewe,et al.  Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis , 2020, International journal of molecular sciences.

[7]  Yoko Ito,et al.  Transcription-dependent cohesin repositioning rewires chromatin loops in cellular senescence , 2020, Nature Communications.

[8]  C. Bishop,et al.  The Bright and Dark Side of Extracellular Vesicles in the Senescence-Associated Secretory Phenotype. , 2020, Mechanisms of ageing and development.

[9]  Xuejuan Gao,et al.  PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis , 2020, Aging.

[10]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[11]  W. Gu,et al.  p53 modifications: exquisite decorations of the powerful guardian , 2019, Journal of molecular cell biology.

[12]  G. Ferbeyre,et al.  The senescence-associated secretory phenotype and its regulation. , 2019, Cytokine.

[13]  M. Narita,et al.  Short-term gain, long-term pain: the senescence life cycle and cancer , 2019, Genes & development.

[14]  T. Fukumoto,et al.  NAD+ metabolism governs the proinflammatory senescence-associated secretome , 2019, Nature Cell Biology.

[15]  Soyoung Lee,et al.  The dynamic nature of senescence in cancer , 2019, Nature Cell Biology.

[16]  G. Scott,et al.  Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype , 2018, Scientific Reports.

[17]  M. Takasugi Emerging roles of extracellular vesicles in cellular senescence and aging , 2018, Aging cell.

[18]  Wiggert A. van Cappellen,et al.  Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging , 2017, Cell.

[19]  Jaewhan Song,et al.  Dynamics of ARF regulation that control senescence and cancer , 2016, BMB reports.

[20]  M. Nakanishi,et al.  Multiple facets of p53 in senescence induction and maintenance , 2016, Cancer science.

[21]  Masashi Narita,et al.  NOTCH1 mediates a switch between two distinct secretomes during senescence , 2016, Nature Cell Biology.

[22]  H. Aburatani,et al.  SCFFbxo22-KDM4A targets methylated p53 for degradation and regulates senescence , 2016, Nature Communications.

[23]  M. Velarde,et al.  Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. , 2016, Cell metabolism.

[24]  Kosuke Tomimatsu,et al.  Translating the effects of mTOR on secretory senescence , 2015, Nature Cell Biology.

[25]  M. Narita,et al.  GATA get a hold on senescence , 2015, Science.

[26]  L. Zender,et al.  mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype , 2015, Nature Cell Biology.

[27]  P. Nelson,et al.  MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation , 2015, Nature Cell Biology.

[28]  H. Gal,et al.  Senescent cells communicate via intercellular protein transfer , 2015, Genes & development.

[29]  Jonathan M. Cairns,et al.  Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53 , 2015, PLoS genetics.

[30]  Yusuke Nakamura,et al.  Late Cornified Envelope Group I, a Novel Target of p53, Regulates PRMT5 Activity , 2014, Neoplasia.

[31]  V. Krizhanovsky,et al.  Physiological and pathological consequences of cellular senescence , 2014, Cellular and Molecular Life Sciences.

[32]  M. Nakanishi,et al.  Necessary and sufficient role for a mitosis skip in senescence induction. , 2014, Molecular cell.

[33]  M. Narita,et al.  Cellular senescence and its effector programs , 2014, Genes & development.

[34]  Darjus F. Tschaharganeh,et al.  Non-Cell-Autonomous Tumor Suppression by p53 , 2013, Cell.

[35]  M. Hande,et al.  Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions , 2012, The EMBO journal.

[36]  F. D. D. Fagagna,et al.  Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation , 2012, Nature Cell Biology.

[37]  C. Lawless,et al.  A senescent cell bystander effect: senescence-induced senescence , 2012, Aging cell.

[38]  Clara Correia-Melo,et al.  Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence , 2012, Nature Communications.

[39]  Simon Tavaré,et al.  Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes , 2011, Science.

[40]  J. Campisi,et al.  p38MAPK is a novel DNA damage response‐independent regulator of the senescence‐associated secretory phenotype , 2011, The EMBO journal.

[41]  J. Campisi,et al.  DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion , 2011, Journal of Cell Science.

[42]  A. Gudkov,et al.  Paradoxical suppression of cellular senescence by p53 , 2010, Proceedings of the National Academy of Sciences.

[43]  J. Campisi,et al.  Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion , 2009, Nature Cell Biology.

[44]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[45]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[46]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[47]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[48]  Aaron Bensimon,et al.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.

[49]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[50]  G. Evan,et al.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.

[51]  Rainer Schmidt,et al.  The cornified envelope: a model of cell death in the skin , 2005, Nature Reviews Molecular Cell Biology.

[52]  Masashi Narita,et al.  Reversal of human cellular senescence: roles of the p53 and p16 pathways , 2003, The EMBO journal.

[53]  S. Lowe,et al.  PML is induced by oncogenic ras and promotes premature senescence. , 2000, Genes & development.

[54]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.